Director/PDMR Shareholding

Convatec Group PLC

07 August 2026

 

07 August 2026

Convatec Group Plc
("Convatec" or "the Company")

Director/PDMR Shareholding 

The Company was notified on 6 August 2026 of the following share purchase transaction in relation to Tobias Hestler, Non-Executive Director of the Company, in respect of ordinary shares of 10 pence each in the Company ("Shares").

The Company was notified that Tobias Hestler had purchased 50,000 ordinary shares of 10 pence each in the Company.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tobias Hestler
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Convatec Group Plc
b)	LEI	213800LS272L4FIDOH92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary share of 10p each in Convatec Group Plc
	Identification code	GB00BD3VFW73
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) £2.258 50,000
d)	Aggregated information
	- Aggregated volume	N/A - single transaction
	- Price	£2.258
e)	Date of the transaction	2026-08-06
f)	Place of the transaction	XLON

Enquiries

James Kerton Company Secretary                                                             
Email: [e-mail] 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com 

 

END